Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Oncology and palliative care indexChapter sections
Role and principlesAssessment and patient selectionBaseline assessmentInterventionsMedicines and treatment safetyTargets, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Cancer prevention and modifiable risk

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Role and principles

Prioritise evidence-based cancer prevention, communicate absolute rather than exaggerated risk, and connect tobacco, alcohol, weight, infection, ultraviolet and occupational interventions to equitable care.

Cancer risk reflects age, inherited susceptibility, random replication error, infections and exposures accumulated across life. Prevention therefore reduces probability rather than guaranteeing protection. Tobacco smoke, alcohol, excess adiposity, ultraviolet radiation and selected occupational agents contribute through distinct mechanisms, while vaccination can prevent persistent oncogenic infection. The greatest population benefit often comes from policies that change availability, price, housing, air quality and workplace exposure rather than relying on individual motivation.

A useful consultation identifies the person's priorities, quantifies exposure without judgement, offers one or two high-value actions and arranges follow-up. Brief tobacco intervention should lead to behavioural and pharmacological cessation support; alcohol discussion should use units and pattern; nutrition and activity advice should be realistic for finances, disability and culture. Claims about supplements or restrictive diets require challenge because high-dose products may harm and have not replaced established prevention.

Risk communication should distinguish relative from absolute risk and acknowledge uncertainty. People with a strong family history, premalignant disease or prior cancer may need specialist surveillance or chemoprevention in addition to general advice. New symptoms still require diagnostic assessment regardless of vaccination, screening attendance or apparently low lifestyle risk.

Key points

  • Tobacco avoidance and cessation remains the highest-impact modifiable cancer-prevention intervention and reduces cardiovascular and respiratory harm at the same time.
  • Alcohol risk rises with consumption and affects several cancer sites; practical reduction advice should avoid implying that any drinking level is cancer-protective.
  • Maintaining a healthy weight, regular activity and a fibre-rich diet support prevention, but counselling must avoid blame because cancer is multifactorial.
  • HPV and hepatitis B vaccination prevent infection-related cancers; vaccine eligibility and catch-up routes follow current national programmes.
  • Sun protection combines shade, clothing and correctly used sunscreen; a tan and intermittent intense exposure do not provide safe adaptation.
  • Occupational and environmental carcinogen control is primarily a systems responsibility using elimination, engineering and protective measures, not worker education alone.
  • Chemoprevention is reserved for defined higher-risk groups after discussion of absolute benefit, bleeding or other harms and competing options.
  • Prevention advice complements, but never replaces, symptom assessment and population screening; a healthy lifestyle cannot rule out cancer.

Assessment and patient selection

Tobacco exposure

Current smoking, recent relapse, household exposure and smokeless products should trigger a specific cessation offer rather than a generic lifestyle warning.

Harmful alcohol pattern

High weekly intake, binge drinking, dependence features or liver disease requires supportive assessment and withdrawal-risk planning before abrupt reduction.

Oncogenic infection risk

Incomplete HPV or hepatitis B vaccination and relevant sexual, household or occupational exposure may create a preventable infection-related cancer risk.

Ultraviolet burden

Outdoor work, sunbeds, repeated burning and immunosuppression increase skin-cancer risk and justify tailored protection and lesion awareness.

Inherited or previous disease

A strong cancer pedigree, premalignant lesion or prior treatment shifts prevention towards genetics, surveillance or defined chemoprevention pathways.

Baseline assessment

  1. 01
    Structured tobacco assessmentFirst step
    Why
    Measure current use, dependence, previous quit attempts and readiness.
    Interpretation and limitations
    Ask product, frequency, first use after waking and prior effective support; carbon monoxide can support engagement but does not diagnose cancer risk.
  2. 02
    Alcohol history and screening tool
    Why
    Identify consumption pattern, dependence and immediate safety needs.
    Interpretation and limitations
    Calculate UK units, include heavy single sessions and assess withdrawal risk; biomarkers do not replace a confidential history.
  3. 03
    Family history and pedigree
    Why
    Recognise patterns requiring inherited-cancer referral.
    Interpretation and limitations
    Document cancer type, age, lineage, multiple primaries and ancestry where relevant; vague family recollection should be verified when decisions are major.
  4. 04
    Vaccination record
    Why
    Establish HPV and hepatitis B protection and catch-up eligibility.
    Interpretation and limitations
    Use current NHS programme criteria; prior infection or sexual activity does not automatically remove every vaccination benefit.
  5. 05
    Occupational exposure review

Interventions

01PrioritiseChoose the highest-value changeFirst stepA routine consultation identifies several potentially modifiable exposures.+
  1. 1Address tobacco first when present, while also identifying alcohol dependence, safeguarding, occupational hazards or symptoms that cannot wait.
  2. 2Use shared decision-making to select a feasible action and explain the expected broader health benefit without promising cancer prevention.
  3. 3Connect the person to commissioned cessation, alcohol, weight-management, vaccination or occupational services and arrange a review point.
02ProtectUse population preventionThe person may be eligible for vaccination or exposure-control measures.+
  1. 1Check current NHS eligibility and previous course completion for HPV or hepatitis B vaccination rather than relying on age assumptions.
  2. 2

Medicines and treatment safety

Combines with behavioural support to improve sustained abstinence from combustible tobacco, the highest-impact modifiable cancer risk for many smokers.

Varenicline for tobacco dependence

Start 1–2 weeks before the quit date: 0.5 mg orally once daily on days 1–3, 0.5 mg twice daily on days 4–7, then 1 mg twice daily from day 8, usually for 12 weeks; reduce for intolerance and follow the SmPC for severe renal impairment.

Review renal function, pregnancy, seizure risk and new or worsening neuropsychiatric symptoms; nausea and abnormal dreams are common, and stopping smoking can itself alter concentrations of medicines affected by tobacco smoke.

Targets, monitoring and follow-up

  • Review tobacco abstinence, cravings, adverse effects and lapses early; treat relapse as information for another supported attempt rather than failure.
  • Monitor alcohol reduction with reported units, wellbeing and dependence safety, adding liver or nutritional assessment when clinically indicated.
  • Reassess weight, activity and dietary goals in a non-stigmatising way and address access, pain, disability, medicines and mental health that constrain change.
  • Record vaccine product and doses accurately, then complete the current schedule and catch-up plan through the NHS programme.
  • For occupational exposure, confirm that system controls changed and that appropriate statutory health surveillance continues where required.
  • During chemoprevention, monitor the agent-specific toxicity and adherence plan and stop when harms outweigh the defined preventive benefit.

Special situations

Prevention is probabilistic

A person can develop cancer despite low exposure, while someone with high exposure may not; this does not invalidate population-risk reduction.

Systems shape behaviour

Price, advertising, housing, food access and working conditions often determine exposure more strongly than knowledge alone.

Vaccination is cancer prevention

Preventing persistent oncogenic infection interrupts a causal pathway rather than merely finding disease earlier.

Supplements can harm

High-dose micronutrients have not reproduced the benefit of food patterns and some increase cancer or treatment risk in specific groups.

Symptoms override reassurance

Screening attendance, vaccination and healthy behaviour must never delay assessment of unexplained bleeding, mass, weight loss or persistent change.

Common pitfalls

  1. 01

    Blaming a patient for a multifactorial disease.

  2. 02

    Quoting relative risk without absolute context.

  3. 03

    Offering vague advice without commissioned support.

  4. 04

    Stopping alcohol abruptly without assessing dependence.

  5. 05

    Using sunscreen as permission for prolonged exposure.

  6. 06

    Assuming supplements prevent cancer in clinical practice.

  7. 07

    Letting prevention replace symptomatic investigation.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Oncology and palliative careOriginal SBA

Highest-impact prevention

A current smoker asks which single change is likely to produce the greatest reduction in their avoidable cancer risk while also improving general health. What is the best response?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Oncology and palliative care topics →
Sources and review status7 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NHS England cancer programmeNational prevention, earlier diagnosis and inequality-reduction priorities across cancer pathways.
  • NHS screening overviewCurrent NHS overview of screening, invitations, benefits, limitations and the need to investigate symptoms separately.
  • UK population screening programme document collectionCurrent programme manuals, standards, pathways, eligibility documents and failsafe resources.
  • NICE shared decision making recommendationsRisk communication, option discussion and decisions aligned with individual values.
  • NICE NG209 tobacco dependenceBehavioural support, medicine choice and timing for treating tobacco dependence.
  • Varenicline Summary of Product CharacteristicsLicensed adult titration, duration, renal adjustment, contraindications and adverse effects.
  • NICE NG12 suspected cancer recognition and referralSymptom-led investigation and referral remain necessary despite prevention or screening activity.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·

Why
Identify current or historical contact with recognised carcinogens.
Interpretation and limitations
Record agent, task, duration and controls, involve occupational health and do not assume personal protective equipment was always adequate.
EscalationFor workplace risk, escalate elimination, substitution and engineering controls through the employer and occupational-health system before relying on individual equipment.
  • 3Reinforce sun avoidance during high exposure, protective clothing and correct sunscreen application, particularly for children and immunosuppressed people.
    • 03EscalateRecognise higher inherited or premalignant riskEscalationFamily pattern, genetic result or previous lesion suggests risk beyond general prevention.+
    1. 1Refer to the appropriate genetics, organ-specific surveillance or prevention service with a documented pedigree and prior pathology.
    2. 2AlternativeDiscuss any chemoprevention using absolute benefit, duration, reproductive issues, bleeding or endocrine harms and alternative risk-reduction strategies.
    3. 3Keep symptom-triggered diagnostic access open because surveillance and prevention reduce risk but do not exclude interval cancer.
    Content changes
    Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom